Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manu...
INmune Bio Inc. (NASDAQ:INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company...
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by...
https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to rep...
